Skip to main content

ImmuneOnco Completes $25 Million Funding for Immunotherapies

ImmuneOnco, a Shanghai oncology immunotherapy company, completed a $25 million Series B financing, led by Lilly Asia Fund. Founded in 2015, the company is developing bi-specific antibodies, novel recombinant proteins, target-specific natural killer (NK) cells, a target-activated NK (TANK) cell therapy, a CAR-T cell therapy and monoclonal antibody drugs that target immune regulation pathways. ImmuneOnco said the capital would support clinical studies of two ImmuneOnco candidates, IMM01, an anti-CD47 fusion protein,  and IMM0306, a bispecific antibody targeting CD47-CD20. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.